Pulmonary Fibrosis News

May 17, 2022May 17, 2022

Angion Biomedica Cleared for Phase 1B Trial of ANG-3070 in IPF

The U.S. Food and Drug Administration (FDA) has given permission for Angion Biomedica to launch a Phase clinical 1b trial to test its experimental anti-fibrotic medication ANG-3070 in people with ... Read more

May 17, 2022May 17, 2022

Generic Version of IPF Therapy Esbriet Now Available in US

Pulmonary Fibrosis News

Sandoz has launched a generic version of Esbriet (pirfenidone) for people with idiopathic pulmonary fibrosis (IPF) in the U.S. The new generic is available now via specialty pharmacies and there ... Read more

May 13, 2022May 13, 2022

Ofev for PF-ILD Now Reimbursed in 7 regions of Canada

Pulmonary Fibrosis News

Ofev (nintedanib), a medicine approved to treat progressive fibrosing interstitial lung disease (PF-ILD), now is available for public reimbursement in Ontario, Quebec, New Brunswick, Newfoundland and Labrador, Alberta, and the ... Read more

May 10, 2022May 10, 2022

FDA Places PLN-74809, IPF Therapy in Phase 2 Trial, on Fast Track

Pulmonary Fibrosis News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to PLN-74809, now in a Phase 2 clinical trial, as a potential treatment for idiopathic pulmonary fibrosis (IPF). ... Read more

May 6, 2022May 6, 2022

Organizations Rally to Help Ukrainian Rare Disease Patients

Pulmonary Fibrosis News

A Russian military plane crash near Tetiana Zamorska’s home in Kyiv, Ukraine, was a sign that it was time for her and her family to leave. The treacherous, 34-hour pilgrimage that ... Read more

May 3, 2022May 4, 2022

GALACTIC-1 Trial of Inhaled IPF Therapy Hits Enrollment Target

Pulmonary Fibrosis News

Less than 14 months after stopping its GALACTIC-1 study for certain patients due to safety concerns, Galecto has hit its enrollment target for the Phase 2b trial — now under ... Read more

May 3, 2022May 3, 2022

Three Lakes, CHEST Team Up to Shorten Lung Disease Diagnosis Time

Pulmonary Fibrosis News

A new multiphase educational collaboration seeks to slash the time it takes for many people to receive a diagnosis of interstitial lung disease (ILD), including pulmonary fibrosis (PF). The Three ... Read more

April 29, 2022April 29, 2022

Vicore Trial Testing New AI App for Anxiety in IPF Enrolls 1st Patient

Pulmonary Fibrosis News

The first patient has been enrolled in a U.S. clinical trial evaluating the efficacy and safety of a new artificial intelligence-based app, called Almee, that’s designed to treat anxiety in ... Read more

April 26, 2022April 26, 2022

‘Broadway Belts for PFF!’ Set to Take Stage April 29 Live and Virtually

Pulmonary Fibrosis News

Organizers say that just a few tickets are still available for this year’s rendition of the Broadway Belts for PFF! fundraiser, benefitting the Pulmonary Fibrosis Foundation (PFF). The annual event, ... Read more

April 22, 2022April 22, 2022

Enrollment Now Complete in ZEPHYRUS-1 Trial of Pamrevlumab

Pulmonary Fibrosis News

Enrollment is now complete in ZEPHYRUS-1, a Phase 3 trial of pamrevlumab, an investigational treatment for idiopathic pulmonary fibrosis (IPF), the therapy’s developer, FibroGen, announced. The randomized, placebo-controlled trial (NCT03955146) ... Read more

April 22, 2022April 22, 2022

Bridge, Shaperon Partner to Develop BBT-209 as Potential IPF Treatment

Pulmonary Fibrosis News

Bridge Biotherapeutics has entered an exclusive in-licensing agreement with Shaperon to develop BBT-209, an investigational therapy for idiopathic pulmonary fibrosis (IPF). “We hope that BBT-209 will become a breakthrough therapy ... Read more

April 19, 2022April 19, 2022

Europe Awaits Proposed New Framework for Sharing Health Data

Pulmonary Fibrosis News

The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health ... Read more

April 15, 2022April 16, 2022

Telehealth Added to Latest Digital-friendly NORD State Report Card

COVID-19 News, Pulmonary Fibrosis News

The National Organization for Rare Disorders (NORD) has updated its State Report Card to make it more digitally friendly and added telehealth to its categories of rare disease policy issues ... Read more

April 12, 2022April 12, 2022

Oral Therapies Boost Alpha-Klotho, Key IPF Protective Protein, in Mice

Pulmonary Fibrosis News

Oral therapies that kill aging cells were found to boost the levels of alpha-Klotho, a protective protein that declines with age and safeguards animals against age-related diseases — including idiopathic ... Read more

April 8, 2022April 8, 2022

Targeting Pro-scarring Immune Cells Thwarts, Reduces PF in Mice

Pulmonary Fibrosis News

Using nanoparticles to deliver an anti-scarring RNA molecule to pro-scarring lung macrophages — a type of immune cell — prevented and reduced lung tissue fibrosis in a mouse model of ... Read more